ClinicalTrials.gg
Not yet recruitingNCT07249125PTMC-3SUpdated Nov 25, 2025

Safety and Quality of Life of Three Treatment Strategies for Low-Risk Papillary Thyroid Microcarcinoma

An observational study in Papillary Thyroid Microcarcinoma, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Xijing Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,630
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective observational patient registry study designed to evaluate the safety and quality of life associated with three treatment strategies for patients diagnosed with low-risk papillary thyroid microcarcinoma (PTMC): surgical resection, thermal ablation, and active surveillance.

The study aims to collect standardized, real-world clinical data from participating centers. Patients will receive one of the three treatment strategies according to clinical judgment and personal preference. The study team will prospectively follow participants to record safety events, disease progression, and patient-reported quality of life outcomes.

By comparing the outcomes among the three treatment groups, this registry seeks to provide evidence to support personalized and evidence-based decision-making for the management of low-risk PTMC.

02

Conditions studied

  • Papillary Thyroid Microcarcinoma
03

In context

Papillary Thyroid Microcarcinoma

24 studies on the registry are indexed under Papillary Thyroid Microcarcinoma; 8 are open to participants now.

This study's planned enrollment of 1,630 is above the median of 480 across 15 observational studies indexed under Papillary Thyroid Microcarcinoma.

Browse Papillary Thyroid Microcarcinoma studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with low-risk papillary thyroid microcarcinoma (maximum diameter ≤1 cm), with no evidence of extrathyroidal extension, lymph node metastasis, or distant metastasis, who choose one of three management strategies: surgical resection, thermal ablation, or active surveillance.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A single papillary thyroid carcinoma (PTC) lesion with a maximum diameter ≤ 1 cm confirmed by imaging.
  • No evidence of extrathyroidal extension on imaging studies.
  • No clinical or radiologic evidence of cervical lymph node .
  • No evidence of distant metastasis.
  • Histopathological confirmation of papillary thyroid carcinoma.
  • The patient has provided written and agrees to select one of the predefined management strategies (surgical resection, thermal ablation, or active surveillance).

Exclusion criteria

Exclusion Criteria:

  • Ultrasound-confirmed tumor with a maximum diameter > 1 cm.
  • Imaging findings (ultrasound/CT/MRI) suggestive of extrathyroidal extension.
  • Tumor located adjacent to critical structures (e.g., trachea, esophagus, or recurrent laryngeal nerve) with possible invasion risk.
  • History of thyroidectomy, radiofrequency/microwave/laser ablation, or radioactive iodine therapy.
  • Failure to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,630 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Surgical Resection

    Participants undergo standard thyroid surgery (lobectomy or total thyroidectomy) for low-risk papillary thyroid microcarcinoma. Outcomes on safety, complications, and postoperative quality of life are collected prospectively.

  • Thermal Ablation

    Participants receive minimally invasive thermal ablation, such as radiofrequency or microwave ablation, for papillary thyroid microcarcinoma. Data include procedural safety, ablation completeness, and patient-reported quality of life.

  • Active Surveillance

    Participants choose active surveillance instead of immediate intervention. Regular follow-up with ultrasound and clinical assessment is conducted to monitor tumor progression, safety events, and quality of life over time.

06

What researchers measure

Primary outcomes

  1. Rate of lymph node metastasis confirmed by imaging and fine-needle aspiration within 10 years

    The proportion of participants who show radiologic evidence of lymph node metastasis confirmed by fine-needle aspiration during 10 years of follow-up.

    Time frame: 10 years

Secondary outcomes

  1. Rate of lymph node metastasis confirmed by imaging and fine-needle aspiration within 5 years

    The proportion of participants with imaging findings suggestive of lymph node metastasis confirmed by fine-needle aspiration at 5 years.

    Time frame: 5 years

  2. Proportion of nodules with ≥3 mm increase in maximal diameter on ultrasound within 5 years (Active Surveillance group)

    Among participants in the active surveillance group, the proportion of thyroid nodules showing an ultrasound-measured increase of at least 3 mm in maximal diameter within 5 years of follow-up.

    Time frame: 5 years

  3. Proportion of nodules with ≥3 mm increase in maximal diameter on ultrasound within 10 years (Active Surveillance group)

    Among active surveillance participants, the proportion of thyroid nodules showing an ultrasound-measured increase of 3 mm or more in maximal diameter within 10 years.

    Time frame: 10 years

  4. Overall survival rate at 10 years

    The proportion of participants who remain alive at 10 years from baseline, regardless of disease status or treatment modality.

    Time frame: 10 years

  5. Conversion rate from active surveillance to surgery

    The proportion of participants initially managed with active surveillance who undergo surgical intervention during the study period.

    Time frame: Up to 10 years

  6. Quality of life scores at 1, 3, 5, and 10 years

    Changes in patient-reported quality of life over time, evaluated using the Fear of Progression Questionnaire-Short Form (FoP-Q-SF) and the Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QoL).

    Time frame: 1, 3, 5, and 10 years

Other outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number and percentage of participants experiencing any study-related adverse events or serious adverse events, collected throughout the study and categorized by severity and relationship to treatment type.

    Time frame: Throughout the 10-year follow-up period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be available upon reasonable request after publication of the main results. Data will be shared with qualified researchers with a methodologically sound proposal, subject to approval by the study steering committee.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Starting 6 months after main publication; available for at least 5 years thereafter.

Access criteria: Researchers may request access through the corresponding author by submitting a proposal and a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2038, 156 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 31, 2038
CompletionEst.
Jun 1, 2039
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07249125
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 31, 2038 (estimated)
Completion
Jun 1, 2039 (estimated)
Last update
Nov 25, 2025

Study contacts

Zhe Wang, Dr
Contact
wangzhe9263@163.com
029-84775271

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion